Print

Purpose

The purpose of this prospective, multicenter study is to assess the long-term safety and effectiveness of the Altaviva™ system for the treatment of UUI

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Candidate for Altaviva™ therapy per Altaviva™ labeling 2. Have a diagnosis of UUI as demonstrated on a 3-day voiding diary by having a minimum of 3 episodes of urinary urge incontinence in 72 hours 3. If taking OAB medications, subjects should be on a stable dose for at least 3 months prior to baseline and willing to remain on stable treatment through completion of the 12-month voiding diary 4. Patient must be willing and able to accurately complete study questionnaires, attend visits, operate the system, and comply with the study protocol 5. Willing and able to provide signed and dated informed consent

Exclusion Criteria

  1. Patient who is not a candidate for Altaviva™ therapy per Altaviva™ labeling, including: - Patients who are considered to be poor surgical candidates or who are at risk for poor wound healing per Altaviva™ labeling - Have progressive, systemic neurological disease - Have clinically significant peripheral neuropathy in the lower leg - Severe, uncontrolled diabetes 2. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component based on physician judgment 3. Current symptomatic urinary tract infection 4. Patients who have been treated with percutaneous tibial nerve stimulation (PTNS)/percutaneous tibial neuromodulation (PTNM) therapy in the past 4 weeks, or longer if the investigator judges that the therapeutic effect is still present 5. Patients who have had treatment of urinary symptoms with botulinum toxin therapy or sacral neuromodulation in the past 6 months 6. History of a prior implantable tibial neuromodulation system 7. Patients who are pregnant or planning to become pregnant during the course of the study 8. Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound study results

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Recruiting Locations

Urology Centers of Alabama
Homewood, Alabama 35209
Contact:
Kaitlin Williams
205-930-0920

Urology of Saint Louis
St Louis, Missouri 63141-8657
Contact:
Mejra Dzinic
314-567-6071

Institute for Female Pelvic Medicine and Reconstructive Surgery
Allentown, Pennsylvania 18103
Contact:
Eileen Taff
610-402-1800

Southern Urogynecology
West Columbia, South Carolina 29169-3456
Contact:
Tina McGready
803-457-7000

More Details

Status
Recruiting
Sponsor
MedtronicNeuro

Study Contact

Mylene Champs
763-526-1627
mylene.champs@medtronic.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.